Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brit Mollenhauer

Showing results (231-240 of 304) with videos related to

Pageof 31
Sort By:
Annals of Neurology|July 11, 2025
Cognitive Performance in Early Neuronal Synuclein Disease with Hyposmia but without Motor Disability: Association with Dopamine Deficiency and Isolated Rapid Eye Movement Sleep Behavior DisorderDaniel Weintraub, Anuprita R Nair, Ryan Kurth, et al.
Annals of Clinical and Translational Neurology|December 20, 2018
The Parkinson's progression markers initiative (PPMI) - establishing a PD biomarker cohortKenneth Marek, Sohini Chowdhury, Andrew Siderowf, et al.
Microbiome|October 7, 2025
Integrated multi-omics highlights alterations of gut microbiome functions in prodromal and idiopathic Parkinson's diseaseRémy Villette, Júlia Ortís Sunyer, Polina V Novikova, et al.
Neurology|September 27, 2013
Unrecognized vitamin D3 deficiency is common in Parkinson disease: Harvard Biomarker StudyHongliu Ding, Kaltra Dhima, Kaitlin C Lockhart, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|February 20, 2020
Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional StudyTanya Simuni, Michael C Brumm, Liz Uribe, et al.
Brain : a Journal of Neurology|September 30, 2021
Blood DNA methylation provides an accurate biomarker of KMT2B-related dystonia and predicts onsetNazanin Mirza-Schreiber, Michael Zech, Rory Wilson, et al.
NPJ Parkinson'S Disease|June 26, 2026
A comprehensive assessment of lifecourse and mortality of Parkinson's disease in the German National CohortKlaus Berger, André Karch, Christina M Lill, et al.
The Lancet. Neurology|July 7, 2019
Safety and efficacy of epigallocatechin gallate in multiple system atrophy (PROMESA): a randomised, double-blind, placebo-controlled trialJohannes Levin, Sylvia Maaß, Madeleine Schuberth, et al.
NPJ Parkinson'S Disease|February 11, 2023
A proteogenomic view of Parkinson's disease causality and heterogeneitySergio Kaiser, Luqing Zhang, Brit Mollenhauer, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|August 17, 2020
Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease ProgressionBrit Mollenhauer, Mohammed Dakna, Niels Kruse, et al.
Pageof 31

Showing results (231-240 of 304) with videos related to

Sort By:
Pageof 31
Annals of Neurology|July 11, 2025
Cognitive Performance in Early Neuronal Synuclein Disease with Hyposmia but without Motor Disability: Association with Dopamine Deficiency and Isolated Rapid Eye Movement Sleep Behavior DisorderDaniel Weintraub, Anuprita R Nair, Ryan Kurth, et al.
Annals of Clinical and Translational Neurology|December 20, 2018
The Parkinson's progression markers initiative (PPMI) - establishing a PD biomarker cohortKenneth Marek, Sohini Chowdhury, Andrew Siderowf, et al.
Microbiome|October 7, 2025
Integrated multi-omics highlights alterations of gut microbiome functions in prodromal and idiopathic Parkinson's diseaseRémy Villette, Júlia Ortís Sunyer, Polina V Novikova, et al.
Neurology|September 27, 2013
Unrecognized vitamin D3 deficiency is common in Parkinson disease: Harvard Biomarker StudyHongliu Ding, Kaltra Dhima, Kaitlin C Lockhart, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|February 20, 2020
Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional StudyTanya Simuni, Michael C Brumm, Liz Uribe, et al.
Brain : a Journal of Neurology|September 30, 2021
Blood DNA methylation provides an accurate biomarker of KMT2B-related dystonia and predicts onsetNazanin Mirza-Schreiber, Michael Zech, Rory Wilson, et al.
NPJ Parkinson'S Disease|June 26, 2026
A comprehensive assessment of lifecourse and mortality of Parkinson's disease in the German National CohortKlaus Berger, André Karch, Christina M Lill, et al.
The Lancet. Neurology|July 7, 2019
Safety and efficacy of epigallocatechin gallate in multiple system atrophy (PROMESA): a randomised, double-blind, placebo-controlled trialJohannes Levin, Sylvia Maaß, Madeleine Schuberth, et al.
NPJ Parkinson'S Disease|February 11, 2023
A proteogenomic view of Parkinson's disease causality and heterogeneitySergio Kaiser, Luqing Zhang, Brit Mollenhauer, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|August 17, 2020
Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease ProgressionBrit Mollenhauer, Mohammed Dakna, Niels Kruse, et al.
Pageof 31